3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
8
Ovarian Neoplasms
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Bevacizumab
187
Fluorouracil
150
Leucovorin
135
Cetuximab
127
Irinotecan
114
Oxaliplatin
108
pembrolizumab
96
Capecitabine
82
IFL protocol
53
Panitumumab
43
Nivolumab
43
regorafenib
42
Folfox protocol
39
Gemcitabine
30
trifluridine tipiracil drug combination
27
Cisplatin
24
Carboplatin
24
atezolizumab
23
Pemetrexed
20
Paclitaxel
20
Drug Therapy
20
130-nm albumin-bound paclitaxel
17
Trastuzumab
14
encorafenib
13
Trifluridine
13
Ipilimumab
13
HMPL-013
13
tislelizumab
12
spartalizumab
11
Docetaxel
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colorectal Neoplasms
×
tisotumab vedotin
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled